Novo Nordisk gained approval for an oral version of Wegovy in December 2025 and launched the pill in January 2026
Pecorelli A, Ferrara F, Messano N, Cordone V, Schiavone ML, Cervellati F, Woodby B, Cervellati C et al (2020) Alterations of mitochondrial bioenergetics, dynamics, and morphology support the theory of oxidative damage involvement in autism spectrum disorder
According to Sarwer and Maccarone, scientists believe these shifts in mood are caused by how the drug changes the brain's central reward pathways by diminishing responses to the neurotransmitter dopamine
A 2022 Call to Action report pointed the finger at genetic, behavioral, environmental and economic factors, including the proliferation of calorie-dense foods
Studies in animal models have shown that GLP-1 activation reduces food-seeking behavior and may decrease the reward-driven aspect of eating that many people with binge eating disorder experience